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  الاْهَداء
 ِإَلى نَبِْع الَحنَاِن َوَملاِكي الَحاِرس .... ِإَلْيِك يَا بَْلَسم َالش ِ َفاء ..  ُأم ِ ي الغَاِليَة
 ِإَلى مُِنيِر َدرِْبي  َومُْلِهم َمِسيرَِتي .... ِإَلْيَك َأيُّهَا الَقْلُب الَكِبير ..  َأِبي الغَاِلي
 الثَّاِني َومَلاَذ ُروِحي .... ِإَلْيِك يَا نَْبَض الَقْلِب ..  َزْوَجِتي الغَاِليَةِإَلى ِنْصِفَي 
 ِإَلى اُلقلوِب الطَّ اِهرَِة وَالنُُّفوِس البَِريَئة ... ِإَليُْكم ْيَا رَيَاِحيَن َحيَاِتي ..  َأوَلَِدي اَلأِعزَّاء
 يَا ُكلَّ آمَاِلي ..  ُأْخِتي الَعِزيزَة َو ِإْخَوِتي اَلأِعزَّاء ِإَلى َمْن َكانُوا َسنَِدي وََعْوِني  .... ِإَليُْكم ْ
 ِإَلى ُمْشِرِفي الَغاِلي ... ِإَلْيَك يَا مَُعل ِِمي ..  ُدْكتُور مَُحمَّد حُجوج
 ِإَلى جَاِمعَِتي الَغرَّاء ... ِإَلْيِك يَا َصرَْح الِعْلِم وَالعَُلمَاء .. َجاِمعَة ُالَقْدس
 ِتي اَلأفَاِضل .. َأَساِتْذِتي الرَّاِئِعينِإَلى َدَكاِتر ْ
 ِإَلى َأْصِدقَاِئي الِذيَن َلم ْيَبَْخُلوا َعليَّ ِبالنُّْصِح وَاِلإْرَشاد
 ِإَلى ُكل ِ َمْن َسانََدِني َحتَّى َأِصَل ِإَلى هَِذِه المَْرَحَلة
 ِإَلى َوَطِني المَْكُلوم .. إِلَى ِفَلْسِطيَن الَحِبيبَة
.هَذا العََمَل المُتَوَاِضع .. أُهِْديُكم َْجِميعَا  
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ABSTRACT 
Medical imaging provides an image for internal parts of organ in non-invasive technique, it is one 
of the fastest areas developing in medicine specially for clinical and research settings. The aim of the 
current study is to mimic the HCC using the dynamic liver phantom displaying functional flow of contrast 
media through the HCC. The proposed phantom design consisted of three types of mimicked soft tissues; 
liver parenchyma; tumors;  and vascular mold. The vascular mold consists of flow part (cylindrical 
medium) located inside the liver parenchyma and this part contains the tumor samples. The phantom are 
made of different ingredients; 4% weight of gelatin powder; 2.6% weight of hydroxyethylcellulose; 0.2% 
weight of benzalkonium chloride; 3.2% weight of propanediol; and 90% weight of water as a volume 
spreader. The tumor model was clearly demonstrated by imaging modalities CT, MRI, and ultrasound. 
The flow phantom or the dynamic part in phantom was well worked. Interestingly, this liver phantom 
enable the employment of the dynamic contrast studies and functional vasculature. In the conclusion, the 
multimodal liver phantom consisting HCC tumor models were produced in simple, low cost and quick 
method within short time. The principle of this technique can be used in different organs in the body. 
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  عن سرطان الكبدالطبي في الكشف  متعدد وسائط التصوير مجسم الكبد ةتقييم فاعلي
 
 إعداد: أسامة محمود شحادة مخامرة
 إشراف: د.محمد الحجوج
 ملخص
 
 
) أحد أكثر الأورام انتشار ا في العالم. و يعتبر الكشف المبكر عن هذا السرطان أفضل طريقة لتوفير العلاج CCHيعتبر سرطان الكبد (
وإنقاذ حياة المرضى. ولكن هناك العديد من التحديات التي تواجه العلماء والباحثين في دراسة بعض الأمراض هذه الأمراض  للحصول 
رة على دراسة هذه الأمراض في داخل جسم الإنسان. ومن هذه التحديات هي عدم وجود على التشخيص المبكر وذلك بسبب عدم القد
مجسم يحاكي الكبد الحقيقي مع وجود بعض الَمراض فيه لإجراء الدراسات والبحوث عليه . لذلك تهدف هذه الدراسة إلى تطوير وتصنيع 
. بحيث )CCH(موية الوظيفية وبعض الأمراض ، مثل سرطان الكبد مجسم  والذي يحاكي نسيج الكبد بحد ذاته وأيضا  يحاكي الأوعية الد
) والتصوير الطبقي المقطعي S/Uفي جميع انواع التصوير الطبي ، مثل التصوير بالموجات فوق الصوتية ( المجسم يمكن استخدام هذا
). يتكون هذا المجسم من ثلاثة أنواع رئيسية مختلفة من الأنسجة وهي نسيج الكبد والنسيج IRM) والتصوير بالرنين المغناطيسي (TC(
ساعة  24والأوعية الدموية الرئيسية. إعداد هذا المجسم بسيط ومنخفض التكلفة ويمكن إعادة استخدامه ويستغرق حوالي  )CCH(المرضي 
المية . ولكن تم تطوير معظم هذه المجسمات لَستخدامها في البحث في للتحضير. هناك بعض مجسمات الكبد المتاحة في الَسواق الع
تطبيقات التصوير بالموجات فوق الصوتية والتصوير الطبقي المقطعي. و تم تطوير بعض المجسمات لتتناسب مع الرنين المغناطيسي. و 
دة. ملونة بحيث يظهر تدفق الدم في الشرايين والَور لكن هذه المجسمات لَ توفر خصائص تدفق الدم ولَ يقدم دراسة ديناميكية للمادة ال
كانت النتائج في هذه الدراسة مرضية وقد حقق الباحثون أهداف الدراسة وتم عمل مجسم  للكبد بحيث كانت خصائص هذا المجسم مشابهة 
ي المتوفرة .  جميع أنواع التصوير الطبلتلك الموجودة في الأنسجة الرخوة في الكبد الحقيقي . و هو ايضا قابل للتطبيق والَستخدام على 
وهذا المجسم الحالي يمكن أن تطبق  الدراسات الديناميكية عليه ويظهر التدفق في الأوعية الدموية.
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CHAPTER ONE 
INTRODUCTION 
1.1 Background   
There are many diseases that affect the liver in the human body. Studying these diseases is very 
important. One of these disease is the hepatocellular carcinoma (HCC). Therefore, studying and 
understanding the anatomy and physiology of the liver are very important. In addition, studying liver 
diseases are also very important. But there are some difficult in studying some diseases inside the human 
body. So In order to study these diseases, it is necessary to have liver phantoms that mimic liver tissue 
with certain diseases and pathologies.  
This study aims at developing a reusable, multimodal liver phantom, which applies functional 
vasculature and displays some pathologies, such as Hepatocellular Carcinoma (HCC). This phantom can 
be used with different modalities, such as Ultrasonography (US), Computed Tomography (CT), and 
Magnetic Resonance Imaging (MRI). 
There are some liver phantoms available on the market, or described in the scientific literature, 
with tumor models and blood vessels structures. Most of these phantoms are developed to be used in the 
research for ultrasound and CT imaging applications. Some phantoms have been developed for MRI. But 
none of them provide blood flow functionality. To the best of our knowledge no known study's done in 
this field with a 3D-multimodal permanent liver phantom displaying functional vasculature and common 
pathologies. 
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The current phantom not only mimic the liver tissue with common pathology, but it also displaying 
functional vasculature with dynamic contrast applications and tri phasic studies (arterial, venous and 
delayed phases).  
1.1.1 Liver anatomy and physiology  
The liver is one of the largest organs in the human body and considered as the largest gland in the 
body with a wide variety of functions. Located in the right side of the abdomen. It is situated just above 
and to the left of the stomach and below the lungs. Weighing between 1.44 and 1.66 kilograms (kg), the 
liver is reddish-brown with a rubbery texture (1). There are four asymmetric lobes of the liver; right and 
left lobes in the front surface separates by falciform ligament, and quadrate and caudate lobe locates in 
the posterior surface(2). Figure 1 shows the anatomy of the liver. 
 
Figure 1 : Anterior and Posterior Views of the Liver. 
1.1.2 Hepatocellular carcinoma (HCC) 
The HCC is one of the most common diseases in the world. It is ranked as the third deadliest 
cancers in the human body (4). Early detection of liver cancer helps to save the patient by providing 
appropriate treatment. HCC occurs most often in people with chronic liver diseases, such as cirrhosis 
caused by hepatitis B or hepatitis C infection (5). 
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1.1.3 HCC diagnosis  
One of the most important ways to diagnose HCC is the non-invasive imaging. The detection of 
HCC depend on the contrast enhancement in CT, MRI and other diagnostic modalities (4). These contrast 
enhancement studies basically have three phases of enhancement: arterial phase, venous phase and 
delayed phase. The HCC lesions take the blood directly from the hepatic artery while the parenchymal 
cells take blood from the portal vein. Because of that the HCC lesions appears hyper-vascularity in arterial 
phase and less bright in the venous phase. This HCC features in contrast enhancement is called classic 
features (2, 4).  
HCC lesions which is more than 2cm can be easily detected by medical imaging modalities 
including US, CT and MRI. However, the optimal management for nodules less than 1 cm showing the 
typical HCC pattern has not yet been observed. (4). Regarding lesions between 1 and 2 cm there is a higher 
sensitivity for MRI ranging between 80 and 90 % compared to 60-75 % with CT. Besides the multimodal 
diagnostic criteria, MRI provides significant benefits with the use of hepatobiliary contrast. 
1.2 Problem Statement 
There are many diseases in the liver that must be studied, but there are many challenges facing 
scientists and researchers because of the limitations to study these diseases in the human body.  
These challenges are the absence of an anthropomorphic 3D-multimodal permanent liver phantom to 
conduct studies and research on it. One example of these diseases is the HCC. Detection of liver cancer 
in its last stages (lesion greater than 2cm) is considered very easy. However, the detection of cancer in its 
early stages (< 1 cm) is very important to save the patient's life. The difficulty is finding the suitable 
technique to detect this size. 
1.3 Justifications (Significance of the Work) 
The new Phantom is important because it provides the researchers with a wide range of research 
experiments considering the 3Rs; in addition, it offers the opportunity to perform control quality to 
4 
  
different medical imaging modalities. This study aimed at developing a liver dynamic phantom, with 
HCC, so that it can be used for research. The phantom was applied on different medical imaging 
modalities, such as CT, MRI, and Ultrasound. 
1.4 Study objectives 
The objective of the study is: 
 To develop and manufacture a 3D-multimodal permanent liver phantom displaying 
functional vasculature and common pathologies.  
 To use this phantom for multimodal image applications (ultrasound (US), CT, and MRI). 
Producing realistic images in commonly used medical imaging modalities. 
The phantom should be suitable for teaching, training, researching and liver imaging tri phasic 
applications. 
1.5 Study Design (System Design) 
This is an experimental study aims to manufacture a 3D-multimodal permanent liver phantom. 
Producing realistic images in commonly used medical imaging modalities. The phantom consists of three 
main components: liver parenchyma; pathology mold; and vascular mold. 
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CHAPTER TWO 
THEORY AND LITRITURE RIVEWW  
Literature studies are mentioned in the article that is included in this research. 
CHAPTER THREE 
MATERIALS AND METHODS 
 
The presented anthropomorphic liver phantom consists of three main model components; liver 
parenchyma, blood vessels, and pathology mold. Different chemical materials with different concentration 
were used to produce the phantom with the three main components that have been mentioned above.   
3.1 The liver Parenchyma 
The liver parenchyma was produced by using different chemical materials with different concentrations. 
The polyvinyl chloride (PVC) human liver simulation mold with size 23x18x13cm and weight 0.62kg 
was used to form the liver shape. The liver parenchyma consists of different percentage of the following 
material: 4 % weight of gelatin powder, 2.6 % weight etherified hydroxyethylcellulose, 0.2 % weight 
benzalkonium chloride, 3.2 % weight propanediol and 90 % weight of water was used as a volume 
spreader.  
3.2 HCC Samples  
The HCC samples were made from two basic materials which are polyurethane combined with 
glycerol and placed in the cylinders inside the phantom. Our manufactured phantom was developed to 
contain three different sized cylinders. Hence, the tumor size can also be easily changed through the 
cylindrical medium.  
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3.3 Blood Vessels  
Three input and output PVC tubes were used instead of vessel trees. The input and output tubes 
are connected by three different sized cylinders. The PVC tubes were connected between the input area 
and the output area, (the central area) which is composed with pathological mold, and it is located inside 
the phantom itself. Dynamic study was performed using these tubes, so there were three types of tubes 
that simulate the liver vessels: input tubes, output tubes and the cylindrical mediums which contain the 
pathologies and located inside the phantom itself, as shown in figure 2.  
 
 
Figure 2 : Blood vessels components of the phantom; (a) input tubes; (b) the cylindrical medium; and (c) the output 
tubes. 
As it is shown in figure 2, the input tubes are connected with the output tubes through a cylindrical 
medium that contains tumor samples. The input tubes are connected with contrast injector to achieve the 
dynamic application with tri phasic study. The output tubes are connected with a suction machine to wash 
out the contrast during the venous and delayed phases. 
3.4 Phantom Formulation Process  
The phantom has been manufactured by the following steps: First, hydroxyethylcellulose, 
benzalkonium chloride, and propanediol were added to the distillated water, mixed together. Then, the 
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mixture was heated to 90°C by using a hot plate magnetic stirrer with magnetic steering at the maximum 
speed of 250 rotations per minute until this mixture reaches the homogenous structure. In a different 
beaker, the gelatine powder is dissolved with distillate water and heated to 50°C. When the powder totally 
dissolved in water, this mixture was added to the first mixture and heated at the same temperature 90°C 
for 30 minutes to form a homogeneous composition  
Finally, after all compounds were made, they were collected together in the liver mold. The input 
tubes are connected with the output tubes through a cylindrical medium, which contains tumor samples. 
Then the phantom was kept at a room temperature. The parenchyma materials should be kept inside the 
liver mold to reduce the erosion, which occurs later in time. 
 
  
8 
  
CHAPTER FOUR 
RESULTS AND DISCUSSION  
Results and discussion are mentioned in the article that is included in this research.  
STUDY PUBLICATION 
This study accepted and presented in 2019 International Conference on Digital Medicine and 
Image Processing (DMIP). The published article of our research study is listed below.  
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2.1 ABSTRACT 
This study aims at developing a reusable, 
multimodal liver phantom, which applies 
functional vasculature and displays some 
pathologies, such as Hepatocellular Carcinoma 
(HCC). This phantom can be used with different 
modalities, such as Ultrasonography (US), 
Computed Tomography (CT), and Magnetic 
Resonance Imaging (MRI). 
The current phantom consisted of different types 
of mimicked tissue; liver parenchyma; HCC and 
major input and output vessels. They are made of 
different ingredients; 4% weight of gelatin 
powder; 2.6% weight of hydroxyethylcellulose; 
0.2% weight of benzalkonium chloride; 3.2% 
weight of propanediol; and 90% weight of water 
as a volume spreader. The selected materials 
mimicked liver tissue under MRI, CT and US.  
The phantom preparation is simple, low cost, 
reusable, and takes about 24 hours for preparation. 
Additionally, comparison of ultrasound images, 
CT, and MRI of real patient’s liver, the phantom’s 
liver tissue with HCC and its structures are well 
simulated. 
Using different steps to cast procedures, the 
researchers fabricated a multimodal liver 
phantom, with dynamic vascular channels, and 
models with different sized pathologies, which 
give a best procedure for training in different 
modalities. This technique can be applied to any 
organ in the body.   
Keywords 
 “Liver phantom” “Dynamic contrast 
enhancement” “MRI” “CT” 
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2.2      INTRODUCTION 
Hepatocellular carcinoma (HCC) is one of the 
most widespread cancers in the world. It is ranked 
as the third deadliest cancers in the human 
body [1]. Early detection of this cancer is 
considered as the best way to provide treatment 
and save patients’ lives [2].The occurrence of this 
cancer is increased in patients with hepatic 
cirrhosis, chronic inflammations, such as Hepatitis 
B- (HBV), Hepatitis C-virus (HCV), alcohol 
consumption, aflatoxin exposure, non-alcoholic 
fatty liver disease (NAFLD), and autoimmunity 
cases [3]. 
The presence of this cancer is detected through its 
distinctive tumor biomarkers, which include α-
fetoprotein (AFP), Des-Gamma-Carboxy 
Prothrombin (DCP), and other markers [4]. 
Additionally, modern techniques in medical 
imaging are among the most important methods of 
detecting this disease. These techniques include 
computed tomography (CT) [5], magnetic 
resonance imaging (MRI) [6], contrast 
enhancement ultrasound (CEUS) [7], and 
fluorodeoxyglucose positron emission 
tomography hybrid with computed tomography 
(FDG PET/CT) [8]. 
In the medical field, many phantoms have been 
developed to help in the assessment of medical 
imaging modalities and research experiments in 
many tasks, such as identifying image quality in 
diagnosis, assisting surgical navigation, helping 
students in their training to perform their tasks, 
and many other different applications. The 
anatomical phantom provides qualitative and 
quantitative estimates of the overall images as well 
as analysis of the clinical image processing 
systems [9]. By means of a phantom model, testing 
of clinical applications assistance systems is 
possible without the need of a real patient. 
The phantom’s properties should be similar to that 
of the real liver soft tissue. The surface should be 
soft enough like real liver. As for CT, 
the Hounsfield units should be the same of real 
liver; and they ought to have the same acoustic 
properties, such as velocity of sound, the 
attenuation coefficient (AC), acoustic impedance 
(Z) and backscatter coefficient in ultrasound. 
Finally, in MRI the relaxation times, T1 and T2 
should be the same as the real liver. It is also 
important to mention that the materials used in the 
manufacturing of Phantoms are as inexpensive and 
available as possible. 
Most of liver phantoms have been designed for CT 
imaging [10, 11, 12, 13], while fewer phantoms 
have been developed to be used in MRI [14, 
15] and ultrasound [16, 17]. Some of these 
phantoms provide blood vascular while some 
others provide a realistic appearance. However, 
Multimodal liver phantoms are still 
uncommon [14, 18]. 
The liver phantoms, which was fabricated for the 
aims of this research have been prepared for CT 
imaging procedures, such as the (1) liver puncture 
test, which was developed for liver biopsy. Liver 
phantoms have used Flex Foam iT-III material 
because this material is elastic and amenable to 
needle puncture [19]. (2) The determination of the 
Iron Hepatic Accumulation using phantom was 
made of agar, which has the same attenuation 
coefficient to the liver parenchyma. It was 
immersed in six tubes with different iron 
concentration [20]. To assess the patient size effect 
onto the hypo vascular liver tumors detection, the 
phantom material that were used were water 
containers with different sizes [12]; however, to 
evaluate C-arm CT accuracy to detect liver 
lesions, the phantom was made by plastic foam to 
represent the patient’s skin [21]. 
In previous studies, many substances with multi-
techniques have been checked to achieve the liver 
phantom realization (Tissue Mimicking 
Material). The soft tissue mimicking materials 
were based on liquid substances, such as 
polyacrylamide (PAA) gel, carrageenan gel, 
polysaccharide gel (PAAG), agar gel, agarose 
gel, polyurethane gel, gelatin-alginate, silicone 
polymer, room-temperature-vulcanizing silicone 
(RTV), and polyethylene glycol diacrylate 
(PEGDA)-based hydrogel [22]. 
This study aimed at developing a liver dynamic 
phantom, with HCC, so that it can be used for 
research. The phantom was applied on different 
medical imaging modalities, such as CT, MRI, and 
Ultrasound. The new Phantom is important 
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because it provides the researchers with a wide 
range of research experiments considering the 
3Rs; in addition, it offers the opportunity to 
perform control quality to different medical 
imaging modalities. 
2.3 MATERIALS AND METHODS 
Phantom Materials, Structure and Production: 
Our Phantom consists of three main components: 
liver parenchyma; pathology mold; and vascular 
mold.  The PVC liver mold with size 23x18x13cm 
and weight 0.62kg was used to form the liver 
shape. Figure () shows the liver mold used in the 
current study. The liver parenchyma was produced 
by using different chemical materials with 
different concentrations as appears in table 1. 
These materials were chosen to mimic the human 
liver, and at the same time to be suitable for 
different imaging modalities. In addition, these 
materials have a high elastic recovery without any 
decrease in their strength, and low modulus also 
have bacterial infection resistance.  
The current study used 4 % weight of gelatin 
powder (Hefei TNJ Chemical Industry Co.,Ltd.); 
2.6 % weight etherified hydroxyethylcellulose 
(Shin Etsu Tylose R HS 100000 YP2); 0.2 % 
weight benzalkonium chloride (StepanguatR 50 
NF) was used as an antibacterial agent; 3.2 % 
weight propanediol (Dupont ZemeanTM) was 
used as a solvent;  and 90 % weight of water was 
used as a volume spreader. The gelatin powder 
with hydroxyethylcellulose addition was used for 
gaining the necessary intensity, density, and 
echogenicity for MRI, CT, and Ultrasound 
imaging, respectively. 
 
Figure 3: The liver mold; (a) is the inferior part of 
mold; (b) is the superior part. 
 
Table 1: Material components of liver phantom 
Gelatine 
powder 
Hydroxyethylcellulose 
Benzalkonium 
chloride 
Propanediol Water 
4 wt % 2.6 wt % 0.2 wt % 3.2 wt % 
90 
wt% 
HCC 5% agarose, 12% glycerol, 83%water. 
 
The tumors components consist of an agarose and 
glycerol for appearing hypo-intensity, 
hypodensity, and hypoechoic in the three 
modalities. The three input PVC tubes and three 
output PVC tubes were used instead of vessel 
trees. The input and output tubes are connected by 
the use of three different sized cylinders. Figure 4 
shows the main phantom parts. 
 
Figure 4: The liver phantom. 
The steps for producing the phantom are as 
follows. First, hydroxyethylcellulose, 
benzalkonium chloride, and propanediol are added 
to the distillated water. They are mixed together, 
and heated to 90°C by using a hot plate magnetic 
stirrer with magnetic steering at the maximum 
speed of 250 rotations per minute, until this 
mixture reaches the homogenous structural. 
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In a different beaker, the gelatine powder is added 
to distillate water, and heated to 50°C. When the 
powder totally dissolves in water, this mixture is 
added to the first mixture and heated at the same 
temperature 90°C for 30 minutes. This time 
guarantees to make the mixture a homogeneous 
composition. Figure 5 shows all of these steps. 
 
Figure 5: Phantom Formulation Process. 
In case of the HCC model, agarose-glycerol 
mixture is used. It is produced by adding these 
components to the distillate water and heated to 
80°C. Then, this compound is poured into silicon 
molds with different sizes; 0.5; 1; and 2cm. The 
new component is cooled in the refrigerator at a 
temperature 4°C for three hours. 
Instead of vessels, PVL tubes were used. They 
were formed from the input area and the output 
area, the medium between them is composed with 
pathological mold, which is located inside the 
phantom itself (figure 6). Tubes are divided into 
three tubes input and three tubes output. Each tube 
is made of non-toxic PVC material with 10 cm in 
length and 14 FG in size, outer diameter of 2.0 
±0.05mm, and thickness ≥ 0.4mm. Input tubes are 
directly connected to the injector device by 
combining them to one syringe. The output tubes 
are also combined to one large tube, which is 
connected into a suction device.   
The use of cylindrical medium was accurately 
modelled. It can investigate the actual transport 
processes in CT and MRI for specific organ or 
location of tumour. This part is the most important 
part in whole phantom. The main cylindrical 
design idea was taken and quoted from pervious 
articles [23] [24] [25] [26]. 
 
Figure 6: Input and output vessels mold. 
After all compounds are made, they are collected 
together in the liver mold. The input tubes are 
connected with the output tubes through a 
cylindrical medium, which contains tumor 
samples. After these arrangements are made, the 
phantom was kept at a room temperature. The 
parenchyma materials should be kept inside the 
liver mold to reduce the erosion, which occurs 
later in time. 
2.4 RESULTS 
1.4.1 Phantom Image Appearance in 
Ultrasound 
Ultrasound was used to scan the phantom. The 
ultrasonic properties were close to the real liver. In 
figure 7, an ultrasound image was obtained for the 
phantom parenchyma as well as the tumour inside 
the phantom. Compared with the normal liver 
parenchyma, the tumour is shown as a hypo-
echoic signal. As shown in figure 8, the Doppler 
ultrasound was also obtained for the tumour mold. 
 
Figure 7: The ultrasound image shows the echogenicity 
of the liver parenchyma inside the phantom. 
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Figure 8: Doppler ultrasound imaging; (a) the signal 
from HCC in red color; (b) the fluid flow through the 
sample. 
Figure 8 shows the Color Doppler ultrasound of 
internal vessels of the phantom with flow. The 
figure shows the Power Doppler ultrasound of a 
vessel structure next to a HCC model.  
1.4.2 Phantom CT-Scan Image Appearance 
The phantom was scanned by using Philips 
Brilliance 64 CT Scanner 64 slice. The protocol 
was obtained with a slice thickness of 0.6mm and 
pixel size 0.5*0.5 mm. The phantom parenchyma 
appeared with homogeneous texture, and the 
Hounsfield unit varied between 20-40 HU (see 
Figure 9). 
 
Figure 9: Phantom appearance in CT images; (a) axial 
cut showing the three cylindrical medium; (b) coronal 
section showing one HCC sample inside the cylinder. 
Telebrix 30 Meglumine (300 mg I/ml) were used 
as a contrast media to check the HCC pattern 
through CT. The tumour models appeared with 
heterogeneous texture. The Hounsfield number for 
the HCC appeared between 80 to 90 HU in arterial 
phase after 22 seconds from injection, 40 to 50 HU 
in venous phase after 50 seconds from injection, 
and 20-30 HU for equilibrium phase after 180 
seconds from injection. Figure 10 illustrates the 
result of contrast media enhancement through the 
sample in CT. The real liver parenchyma tissue 
without contrast media was approximately 50HU; 
however, with contrast media in arterial phase, it 
was around 90-125 HU. This means that phantom 
structures had the same appearances of the real 
liver. 
 
 
Figure 10: CT axial images; (a) pre-contrast; (b) 
arterial phase after 22 sec (tumor is clearly bright); (c) 
venous phase after 50 sec (tumor is slightly bright); and 
(d) delayed phase after 180 sec (tumor clearly washout). 
 
1.4.3 3D Reconstruction from phantom CT 
image and Model Registration A 
The 3D planning model was obtained by using 
voxel size of phantom increased up to 1×1×1 mm. 
The 3D reconstruction was represented in figure 
11. 
 
Figure 11: CT reconstruction images; (a) shows 
anterior surface; (b) shows posterior surface; (c) shows 
inferior surface; and (d) shows HCC inside the 
phantom. 
1.4.4 Phantom MRI image Appearance 
The phantom imaging was performed by using a 
1.5-T MRI unit (MAGNETOM Aera, Siemens 
Healthcare, Erlangen) with a 48-radiofrequency 
channel system, which provided a maximum 
gradient strength of 45 mT/m and a peak slew rate 
of 200 mT/m/ msec. 72 images were recorded, 
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each with 512 × 512 pixels. The FOV reading was 
380 mm, FOV phase was 81.3%, and the slice 
thickness was 3.0 mm.  Figure 10 shows the 
images of the liver phantom depicted in Fig 12. 
The figure 4.13 shows the study sample with a 
2.5wt% concentration of gelatin after the sixth 
week. The figure shows one of the readings that 
were taken to calculate the signal intensity of the 
materials fabricated in the phantom, which was 
estimated at 181. 
 
Figure 12: Liver phantom model; T1 maps of the 
phantom layer made of gelatin 2.5wt%; the phantom 
shows axial cross section of the three cylindrical, which 
contains the tumors sample. 
 
1.5 DISCUSSION 
The current method allows fabricating multimodal 
phantoms with reusable parts. The parenchyma 
can be reused to produce a new phantom. The 
phantom can easily release by removing the old 
liver only with effortless process. The hot water 
can be used to remove the liver parenchyma 
method. The gel-based liver parenchyma can be 
stocked in the closed counter at a room 
temperature. 
Because the output orifice of cylindrical medium 
is located outside the phantom, the tumour size can 
also be easily changed through the cylindrical 
medium. It is easy to reuse it again with different 
pathological samples. 
The limitations of current study consisted of the 
incorporation of exact representations of vessels as 
different types, e.g. portal and hepatic veins. 
Future work is needed to mimic the vessels with 
dynamic phantom and use different pathology 
models. The study can be used to perform typical 
HCC pattern. In addition of that, the chemical 
bonds between the phantom components of the 
phantom should be detected using some devices 
such as Fourier Transform Infrared Spectroscopy 
(FTIR) or Raman spectroscopy. Also, the 
temperature of the phantom should be adjusted at 
specific degree to check the actual effects of time 
on signal intensity. 
The current phantom was designed to mimic the 
HCC and normal liver tissue characteristics 
including acoustic properties, Hounsfield unit, and 
signal intensity. Therefore, the phantom can 
support users with standardized environment in 
different medical modalities. The multimodal 
phantoms can be used for different purposes, such 
as  research, image-designing system tests; quality 
control of imaging systems; the performance of 
comparison between imaging systems; 
establishing new protocols with different imaging 
systems; surgery action training for liver surgery; 
needle guided puncture of lesions; and assessment 
of 3D and reconstruction based on sizes and 
shapes knowledge. 
1.6 CONCLUSION 
 The study has shown that the phantom mimics the 
real liver tissue with HCC sample. The phantom is 
efficient to be applied on possible 
training, scientific experiments, and for testing 
different purposes. The current phantom is a very 
suitable for different medical purposes such as 
training the operator, surgical guided and 
treatment monitoring by using different modalities 
including: CT, ultrasound, and MRI. The typical 
HCC pattern appearance in CT and MRI were 
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CHAPTER FIVE 
CONCLUSION AND RECOMMENDATIONS 
This chapter include brief overview about, conclusion, future perspective, and appendices. 
5.1 Conclusion 
The current method allows fabricating multimodal phantom with dynamic contrast study, 
displaying functional vasculature and common pathologies with different size.  The tumor size can 
also be easily changed through the cylindrical medium.  The current phantom was designed to 
mimic the HCC and normal liver tissue characteristics including acoustic properties,  
Hounsfield unit, and signal intensity.  
The study has shown that the phantom mimics the real liver tissue with HCC sample.  It 
can be applied on possible training, scientific experiments, and for testing different purposes.  The 
current phantom is a very suitable for different medical purposes such as training the operator and 
surgical guided by using different modalities including CT, ultrasound, and MRI.   
This multimodal phantom can be used for different purposes, such as research, image-
designing system tests, quality control of imaging systems, needle guided puncture of lesions, 
comparison between imaging systems, establishing new protocols with different imaging systems 
and surgery action training for liver surgery. 
5.2 Future Perspectives 
Future work is to mimic the vessels with dynamic phantom and use different pathology 
models for different organs with different pathologies.  
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The materials and methodology used in this study can be applied to different studies that 
mimic different organs and pathology.  
Various studies can be conducted on the phantom in order to verify the chemical, physical, 
mechanical and electrical properties of the materials used in the manufacture of the phantom. 
Appendices. 
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